Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Tesla sales careened lower in Germany in January, as sales of the electric vehicle company headed by Elon Musk tumble across Europe. The TV spot marks the artificial-intelligence company's biggest ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

We disagree as this is an AI Arms Race and Alphabet is making the right moves at the right time. While this quarter was not a ...

Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

An example is at Google. Anat Ashkenazi, the former CFO of Eli Lilly and Company, became the CFO of Google and Alphabet on July 31. Ashkenazi succeeded Ruth Porat who was CFO for almost 10 years.

In 2024, Google appointed Anat Ashkenazi, former CFO of Eli Lilly, as its new finance chief, succeeding Ruth Porat after her nearly decade-long tenure. Similarly, Target Corporation brought in Jim ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...